Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By

1 型糖尿病:Zn2 增强 β 细胞死亡

基本信息

  • 批准号:
    7143563
  • 负责人:
  • 金额:
    $ 31.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Type 1 diabetes is an autoimmune disease caused by T-lymphocyte generated ROS-mediated destruction of the insulin-producing beta cells. Mitochondrial and glycolytic enzyme dysfunction, pyridine cofactor and triosephosphate imbalance, and poly-ADP ribose polymerase (PARP) activation have each been implicated, suggesting that a metabolic mediator such as the NAD+/NADH ratio may be affected. We propose that zinc (Zn2+) potentiates some of these dysfunctions. Zn2+ is prevalent in the pancreas where it is released from beta-cell insulin secretory granules, both free and bound to insulin, and is taken back up into neighboring beta-cells. Zn2+ toxicity was recently implicated in islet-cell death that occurs secondarily to acute streptozotocin (STZ) exposure in vitro and in vivo. We show that niacinamide, pyruvate, NAD+, and sirtinol prevent Zn2+toxicity in neurons and beta-cells by counteracting the Zn2+-induced decrease in NAD+ levels in vitro (subset work in vivo). Niacinamide was shown to be an effective prophylactic for human, and animal type-1 diabetes if given before onset. Recently, we demonstrated that NOD animals have abnormally strong Zn2+ staining of islets as they age, and pyruvate attenuates beta-cell death, and diabetes in the NOD model. We propose that the autoimmune reaction stresses beta-cells which in turn release toxic concentrations of Zn2+. This causes death of adjoining beta-cells by NAD+depletion. Manipulations which raise [NAD+]i or lower [Zn2+]i will be protective. Niacinamide is an NAD+catabolism inhibitor and the precursor of NAD+, and the conversion of pyruvate to lactate acts to restore NAD+levels and metabolic enzymes, thereby reducing death. Sirtinol is a specific inhibitor of the sirtuin pathway which consists of NAD+dependent protein deacetylases. In specific aim 1, we will 1) measure [Zn2+]i, and 65Zn2+accumulation in isolated islets induced by Zn2+, cytokine, and streptozotocin exposures; 2) Determine the effects of these exposures on beta-cell metabolism, and the ability of pyruvate, niacinamide, and sirtinol to restore metabolism; 3) Lentiviral or genetic manipulation of NAD+ synthesis and catabolism will be used to explore the specific pathways involved in Zn2+ mediated NAD+ loss and beta-cell death. In specific aim 2, we will determine the ability of pyruvate, and niacinamide to reduce the metabolic derangements and diabetic incidence in the NOD model. Zinc transporter 5 (ZnT5) was suggested to load Zn2+ into secretory vesicles in beta-cells. SIRT-1 is the founding member of the sirtuin pathway which was implicated in neuronal and beta-cell Zn2+ toxicity, and Wlds overexpresses an NAD+synthetic enzyme. In aim 3, we will characterize ZnT5 -/-, +/+, Wlds, and SIRT-1-/-animals for diabetes incidence, beta-cell death, Zn2+ staining, and insulin release after MLDS streptozotocin-exposure. These experiments will test novel therapeutic compounds (pyruvate, sirtinol) and mechanisms (NAD+loss, sirtuins) involved in Zn2+ mediation of beta-cell death in type-1 diabetes.
描述(申请人提供):1型糖尿病是一种自身免疫性疾病,由T淋巴细胞产生的ROS介导的破坏产生胰岛素的β细胞引起。线粒体和糖酵解酶功能障碍,吡啶辅因子和磷酸丙糖失衡,以及多聚腺苷二磷酸核糖聚合酶(PARP)的激活都与此有关,这表明代谢介质,如NAD+/NADH比率可能受到影响。我们认为锌(Zn~(2+))增强了其中的一些功能障碍。锌离子普遍存在于胰腺中,在那里它从β细胞胰岛素分泌颗粒中释放出来,无论是游离的还是与胰岛素结合的,并被带回邻近的β细胞。在体外和体内,锌离子毒性与急性链脲佐菌素(STZ)暴露引起的胰岛细胞死亡有关。我们发现,烟酰胺、丙酮酸、NAD+和水飞蓟醇在体外通过对抗锌离子诱导的NAD+水平的下降(体内工作亚组)来阻止锌离子对神经元和β细胞的毒性。烟酰胺被证明是一种有效的预防人类和动物1型糖尿病的药物。最近,我们证明了NOD动物随着年龄的增长,胰岛的锌离子染色异常强烈,丙酮酸可以减轻NOD模型中的β细胞死亡和糖尿病。我们认为,自身免疫反应给β细胞带来压力,而β细胞又释放出有毒浓度的锌离子。这会导致邻近的β细胞因NAD+耗尽而死亡。升高[NAD+]i或降低[Zn2+]i的操作将是保护性的。烟酰胺是一种NAD+分解代谢抑制剂,也是NAD+的前体,丙酮酸转化为乳酸的作用是恢复NAD+水平和代谢酶,从而减少死亡。Sirtinol是sirtuin途径的一种特异性抑制剂,sirtuin途径由NAD+依赖的蛋白去乙酰基酶组成。在特定的目标1)中,我们将1)测量由锌离子、细胞因子和链脲佐菌素暴露引起的胰岛内[锌离子]i和65锌离子的积累;2)确定这些暴露对β细胞代谢的影响,以及丙酮酸、烟酰胺和水飞蓟醇恢复代谢的能力;3)利用慢病毒或基因操作NAD+的合成和分解代谢,以探索锌2+介导的NAD+丢失和β细胞死亡的具体途径。在具体目标2中,我们将确定丙酮酸和烟酰胺在NOD模型中减少代谢紊乱和糖尿病发生率的能力。锌转运蛋白5(ZnT5)可将锌离子装载到胰岛β细胞的分泌囊泡中。Sirt-1是sirtuin途径的创始成员,sirtuin途径与神经元和β细胞的锌毒性有关,而Wlds过度表达NAD+合成酶。在目标3中,我们将研究在MLDS链脲佐菌素暴露后,糖尿病发病率、β细胞死亡、锌染色和胰岛素释放方面的锌锌染色、+/+、Wlds和SIRT-1-/-动物的特征。这些实验将测试新的治疗化合物(丙酮酸、sirtinol)和机制(NAD+丢失、sirtuins),这些机制涉及锌离子介导1型糖尿病患者的β细胞死亡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTIAN Thomas SHELINE其他文献

CHRISTIAN Thomas SHELINE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTIAN Thomas SHELINE', 18)}}的其他基金

Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By Sirtuin-Mediated NAD+ Loss
1 型糖尿病:Sirtuin 介导的 NAD 损失导致 Zn2 增强 β 细胞死亡
  • 批准号:
    7998878
  • 财政年份:
    2010
  • 资助金额:
    $ 31.26万
  • 项目类别:
Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By Sirtuin-Mediated NAD+ Loss
1 型糖尿病:Sirtuin 介导的 NAD 损失导致 Zn2 增强 β 细胞死亡
  • 批准号:
    7624970
  • 财政年份:
    2006
  • 资助金额:
    $ 31.26万
  • 项目类别:
Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By Sirtuin-Mediated NAD+ Loss
1 型糖尿病:Sirtuin 介导的 NAD 损失导致 Zn2 增强 β 细胞死亡
  • 批准号:
    7393678
  • 财政年份:
    2006
  • 资助金额:
    $ 31.26万
  • 项目类别:
Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By Sirtuin-Mediated NAD+ Loss
1 型糖尿病:Sirtuin 介导的 NAD 损失导致 Zn2 增强 β 细胞死亡
  • 批准号:
    7248822
  • 财政年份:
    2006
  • 资助金额:
    $ 31.26万
  • 项目类别:
Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By Sirtuin-Mediated NAD+ Loss
1 型糖尿病:Sirtuin 介导的 NAD 损失导致 Zn2 增强 β 细胞死亡
  • 批准号:
    7741877
  • 财政年份:
    2006
  • 资助金额:
    $ 31.26万
  • 项目类别:
CLONING OF AND REQUIREMENT FOR TAR BINDING PROTEIN TRP-1
焦油结合蛋白TRP-1的克隆和要求
  • 批准号:
    2059039
  • 财政年份:
    1993
  • 资助金额:
    $ 31.26万
  • 项目类别:
ZINC NEUROTOXICITY
锌的神经毒性
  • 批准号:
    6639439
  • 财政年份:
    1991
  • 资助金额:
    $ 31.26万
  • 项目类别:
ZINC NEUROTOXICITY
锌的神经毒性
  • 批准号:
    6539737
  • 财政年份:
    1991
  • 资助金额:
    $ 31.26万
  • 项目类别:
ZINC NEUROTOXICITY
锌的神经毒性
  • 批准号:
    6738162
  • 财政年份:
    1991
  • 资助金额:
    $ 31.26万
  • 项目类别:
Imaging Core
成像核心
  • 批准号:
    8668115
  • 财政年份:
  • 资助金额:
    $ 31.26万
  • 项目类别:

相似海外基金

TP-R: a novel mediator of obesity-linked insulin resistance in humans
TP-R:人类肥胖相关胰岛素抵抗的新型介质
  • 批准号:
    10709488
  • 财政年份:
    2021
  • 资助金额:
    $ 31.26万
  • 项目类别:
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
p53 突变三阴性乳腺癌的精准代谢治疗
  • 批准号:
    10454390
  • 财政年份:
    2021
  • 资助金额:
    $ 31.26万
  • 项目类别:
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
p53 突变三阴性乳腺癌的精准代谢治疗
  • 批准号:
    10294457
  • 财政年份:
    2021
  • 资助金额:
    $ 31.26万
  • 项目类别:
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
p53 突变三阴性乳腺癌的精准代谢治疗
  • 批准号:
    10621315
  • 财政年份:
    2021
  • 资助金额:
    $ 31.26万
  • 项目类别:
TP-R: a novel mediator of obesity-linked insulin resistance in humans
TP-R:人类肥胖相关胰岛素抵抗的新型介质
  • 批准号:
    10426085
  • 财政年份:
    2021
  • 资助金额:
    $ 31.26万
  • 项目类别:
Structural Basis of HDAC Substrate Specificity and Inhibition
HDAC 底物特异性和抑制的结构基础
  • 批准号:
    9394954
  • 财政年份:
    2017
  • 资助金额:
    $ 31.26万
  • 项目类别:
Unraveling the Origin of Pyrazinamide's Synergy with other anti-TB Drugs
揭示吡嗪酰胺与其他抗结核药物协同作用的起源
  • 批准号:
    9079347
  • 财政年份:
    2015
  • 资助金额:
    $ 31.26万
  • 项目类别:
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
肿瘤微环境中治疗性蛋白质合成的细胞生物工厂
  • 批准号:
    9114273
  • 财政年份:
    2015
  • 资助金额:
    $ 31.26万
  • 项目类别:
Sphingolipid-mediated dysregulation of glucose and energy homeostasis by POMC neurons
POMC 神经元鞘脂介导的葡萄糖和能量稳态失调
  • 批准号:
    9050560
  • 财政年份:
    2015
  • 资助金额:
    $ 31.26万
  • 项目类别:
NAAA Inhibitors for pain and inflammation
NAAA 疼痛和炎症抑制剂
  • 批准号:
    8903152
  • 财政年份:
    2015
  • 资助金额:
    $ 31.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了